Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CAMX
CAMX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CAMX News
Camurus announces favorable topline findings for CAM2056, a monthly depot formulation of semaglutide.
Nov 10 2025
Newsfilter
Camurus Receives UK Approval for Oczyesa® to Treat Acromegaly
Aug 28 2025
Newsfilter
Camurus' Oczyesa® receives marketing authorization for treatment of acromegaly in the EU
Jul 01 2025
Newsfilter
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients
Jun 18 2025
Newsfilter
Eli Lilly Strikes $870 Million Deal to Develop Long-Acting Obesity Treatments
Jun 09 2025
TipRanks
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Jun 03 2025
Newsfilter
Why Elevance Health Shares Are Surging Premarket On Wednesday?
May 28 2025
Benzinga
Uber, iFood Unite In Brazil To Offer One-Stop App Convenience
May 15 2025
Benzinga
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU
Apr 25 2025
Newsfilter
CME Group Expands Nikkei Futures Offerings, Boosts Japanese Equity Derivatives
Oct 01 2024
Benzinga
Eni's Q2 Profit Declines But Beats Expectations: Shares Rise On Strong Production
Jul 26 2024
Benzinga
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Jul 15 2024
Newsfilter
Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients
Jul 15 2024
PRnewswire
European Energy Giant Eni Seals Extended Gas Deal With Vår Energi: Details
Jul 01 2024
Benzinga
New publication shows effectiveness data for weekly and monthly buprenorphine injections in treating opioid dependence in individuals using fentanyl
Jun 25 2024
Newsfilter
Show More News
